NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04498403,"A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis",https://clinicaltrials.gov/study/NCT04498403,,TERMINATED,"This study is a Phase 3, multicenter, open-label, long-term safety extension study of Studies C3291032 and C3291031 in Japanese pediatric and adult participants with mild to moderate Atopic Dermatitis (AD).",YES,Atopic Dermatitis,DRUG: Crisaborole 2%,"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), An adverse events (AE) is any untoward medical occurrence in clinical investigation participant administered a product or medical device; event need not necessarily to had a causal relationship with treatment or usage. SAEs: an AE resulting in any of following outcomes/deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are events between first dose of study drug and up to 28 days after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events., Baseline up to 28 days after last dose of study drug (maximum up to 12 weeks)",,,Pfizer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,40,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,C3291027,2020-09-14,2020-12-18,2020-12-18,2020-08-04,2021-06-14,2021-08-12,"Shirao Clinic of Pediatrics and Pediatric Allergy, Hiroshima-shi, Hiroshima, 734-0023, Japan|Chitose dermatology and plastic surgery clinic, Chitose Shi, Hokkaido, 066-0021, Japan|Takagi Dermatological Clinic, Obihiro, Hokkaido, 080-0013, Japan|Yoshimura Child Clinic, Akashi-City, Hyōgo, 674-0068, Japan|Iryouhoujinshadan Yamayurikai Tsujino. Kodomo Clinic, Kobe-City, Hyōgo, 658-0082, Japan|Noguchi Dermatology Clinic, Kamimashiki-gun, Kumamoto, 861-3101, Japan|Yoshioka Dermatology Clinic, Neyagawa, Osaka, 572-0838, Japan|Mildix Skin Clinic, Adachi-ku, Tokyo, 120-0034, Japan|Yoga Allergy Clinic, Setagaya-ku, Tokyo, 158-0097, Japan|Sugamo Kobayashi Derma Clinic, Toshima-Ku, Tokyo, 170-0002, Japan|Hoshikuma Dermatology・Allergy Clinic, Fukuoka, 814-0171, Japan","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/03/NCT04498403/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/03/NCT04498403/SAP_001.pdf"
